| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.32 | 2e-21 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.31 | 8e-20 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.27 | 3e-17 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.36 | 1e-15 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.27 | 4e-15 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | 0.23 | 1e-11 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.22 | 6e-10 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-09 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.31 | 2e-09 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | 0.37 | 1e-07 |